AlphaCrest Capital Management’s Synopsys SNPS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-9,955
Closed -$3.04M 977
2022
Q3
$3.04M Buy
9,955
+2,674
+37% +$905K 0.19% 98
2022
Q2
$2.21M Sell
7,281
-1,245
-15% -$376K 0.11% 274
2022
Q1
$2.84M Sell
8,526
-1,153
-12% -$360K 0.16% 135
2021
Q4
$3.57M Sell
9,679
-5,389
-36% -$1.82M 0.13% 167
2021
Q3
$4.51M Buy
15,068
+6,222
+70% +$1.89M 0.23% 72
2021
Q2
$2.44M Sell
8,846
-1,590
-15% -$404K 0.1% 294
2021
Q1
$2.59M Buy
10,436
+5,894
+130% +$1.5M 0.14% 183
2020
Q4
$1.18M Sell
4,542
-1,741
-28% -$402K 0.1% 263
2020
Q3
$1.34M Buy
6,283
+1,903
+43% +$387K 0.15% 171
2020
Q2
$854K Sell
4,380
-6,908
-61% -$1.14M 0.14% 191
2020
Q1
$1.45M Buy
11,288
+3,453
+44% +$491K 0.18% 152
2019
Q4
$1.09M Sell
7,835
-4,967
-39% -$681K 0.09% 311
2019
Q3
$1.76M Sell
12,802
-6,189
-33% -$837K 0.11% 293
2019
Q2
$2.44M Buy
18,991
+12,491
+192% +$1.5M 0.21% 106
2019
Q1
$748K Buy
6,500
+3,818
+142% +$378K 0.11% 294
2018
Q4
$226K Buy
+2,682
New +$238K 0.07% 566

Other funds holding SNPS

AlphaCrest Capital Management's SNPS Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Synopsys (SNPS) in Q4 2022, closing a stake of 9,955 shares — an estimated $3.04M sold.

AlphaCrest Capital Management first reported a position in SNPS in Q4 2018 and held it in 16 quarters. The position peaked at $4.51M in Q3 2021. 921 funds tracked by Wall St. Rank hold SNPS as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Synopsys position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 9,955 Synopsys shares in Q4 2022, an estimated $3.04M.
  • AlphaCrest Capital Management first reported a position in Synopsys in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's Synopsys position peaked at $4.51M in Q3 2021.
  • 921 funds tracked by Wall St. Rank held Synopsys as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.